SAVA
Price
$1.77
Change
+$0.07 (+4.12%)
Updated
May 9 closing price
Capitalization
82.12M
81 days until earnings call
VERV
Price
$4.23
Change
-$0.25 (-5.58%)
Updated
May 9 closing price
Capitalization
399.36M
89 days until earnings call
Ad is loading...

SAVA vs VERV

Header iconSAVA vs VERV Comparison
Open Charts SAVA vs VERVBanner chart's image
Cassava Sciences
Price$1.77
Change+$0.07 (+4.12%)
Volume$1.15M
Capitalization82.12M
Verve Therapeutics
Price$4.23
Change-$0.25 (-5.58%)
Volume$2.11M
Capitalization399.36M
SAVA vs VERV Comparison Chart
Loading...
SAVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SAVA vs. VERV commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SAVA is a Buy and VERV is a Hold.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (SAVA: $1.77 vs. VERV: $4.23)
Brand notoriety: SAVA and VERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SAVA: 77% vs. VERV: 63%
Market capitalization -- SAVA: $82.12M vs. VERV: $399.36M
SAVA [@Biotechnology] is valued at $82.12M. VERV’s [@Biotechnology] market capitalization is $399.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SAVA’s FA Score shows that 1 FA rating(s) are green whileVERV’s FA Score has 1 green FA rating(s).

  • SAVA’s FA Score: 1 green, 4 red.
  • VERV’s FA Score: 1 green, 4 red.
According to our system of comparison, both SAVA and VERV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SAVA’s TA Score shows that 4 TA indicator(s) are bullish while VERV’s TA Score has 3 bullish TA indicator(s).

  • SAVA’s TA Score: 4 bullish, 4 bearish.
  • VERV’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, SAVA is a better buy in the short-term than VERV.

Price Growth

SAVA (@Biotechnology) experienced а +9.94% price change this week, while VERV (@Biotechnology) price change was -18.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

SAVA is expected to report earnings on Jul 30, 2025.

VERV is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VERV($399M) has a higher market cap than SAVA($82.1M). SAVA (-25.000) and VERV (-25.000) have similar YTD gains . SAVA has higher annual earnings (EBITDA): -141.15M vs. VERV (-221.91M). VERV has more cash in the bank: 524M vs. SAVA (129M). SAVA has less debt than VERV: SAVA (0) vs VERV (70M). VERV has higher revenues than SAVA: VERV (32.3M) vs SAVA (0).
SAVAVERVSAVA / VERV
Capitalization82.1M399M21%
EBITDA-141.15M-221.91M64%
Gain YTD-25.000-25.000100%
P/E RatioN/AN/A-
Revenue032.3M-
Total Cash129M524M25%
Total Debt070M-
FUNDAMENTALS RATINGS
SAVA: Fundamental Ratings
SAVA
OUTLOOK RATING
1..100
28
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
90
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SAVAVERV
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 17 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
SAVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTM0.980.05
+5.82%
Castellum
ENGQF20.920.92
+4.60%
ENGIE SA
SOMMY12.280.26
+2.14%
Sumitomo Chemical Co., Ltd.
LQMT0.11N/A
+1.10%
Liquidmetal Technologies, Inc.
ACSAY12.650.06
+0.48%
ACS Actividades De Construccion Y Servicios SA

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with CRSP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
+4.12%
CRSP - SAVA
35%
Loosely correlated
-1.44%
IBRX - SAVA
29%
Poorly correlated
-0.96%
LXRX - SAVA
26%
Poorly correlated
+1.73%
AMRN - SAVA
26%
Poorly correlated
-2.80%
VKTX - SAVA
26%
Poorly correlated
-1.08%
More

VERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, VERV has been loosely correlated with BEAM. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if VERV jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VERV
1D Price
Change %
VERV100%
-5.58%
BEAM - VERV
59%
Loosely correlated
+0.93%
CRSP - VERV
55%
Loosely correlated
-1.44%
PRME - VERV
50%
Loosely correlated
-1.52%
RXRX - VERV
50%
Loosely correlated
-1.37%
ARWR - VERV
50%
Loosely correlated
-1.66%
More